- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04503668
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
February 26, 2024 updated by: University of Michigan Rogel Cancer Center
Phase III Randomized Control Trial Investigating Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients With Gynecologic Malignancies Receiving Every 3-week Carboplatin and Paclitaxel Chemotherapy
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Rogel Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of gynecologic malignancy
- No chemotherapy in the last 12 months
- Scheduled to receive Carboplatin (AUC>=4) and Paclitaxel every three weeks
- ECOG performance status 0 or 1
- English speaking
- Willing and able to provide informed consent
- Laboratory values within protocol-defined parameters
- No vomiting in the 24 hours prior to initiating chemotherapy
- If childbearing potential exists, negative pregnancy test within 7 days prior to registration
Exclusion Criteria:
- Significant cognitive compromise
- History of CNS disease (e.g. brain metastases, seizure disorder, dementia)
- Current or recent (within 30 days) treatment with another antipsychotic agent (antidepressant medications are OK)
- Concurrent radiotherapy treatment
- Known hypersensitivity to olanzapine
- Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the last six months
- History of diabetes mellitus on medication (insulin or oral glycemic agent)
- Alcohol abuse / chronic alcoholism
- History of closed angle glaucoma
- Current enrollment in other clinical trials
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nk1-RA
Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
|
8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
20 mg IV on day 1 pre-chemotherapy
150 mg IV on day 1 pre-chemotherapy
Other Names:
5-10 mg by mouth, available as needed, every 6 hours, days 1-5
|
Experimental: Olanzapine
Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.
|
8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
20 mg IV on day 1 pre-chemotherapy
5-10 mg by mouth, available as needed, every 6 hours, days 1-5
5 mg by mouth on days 1-4 of chemotherapy (taken at night)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of complete response in the overall time period (0 - 120 hours post-chemotherapy)
Time Frame: At day 6
|
Complete response (CR) is defined as no episodes of vomiting and no use of rescue antiemetic medications.
Patient reported diaries will be used to measure this outcome.
|
At day 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of complete response in the acute time period (0 - 24 hours post-chemotherapy)
Time Frame: At day 2
|
Complete response (CR) is defined as no episodes of vomiting and no use of rescue antiemetic medications.
Patient reported diaries will be used to measure this outcome.
|
At day 2
|
Rate of complete response in the delayed time period (24 - 120 hours post-chemotherapy)
Time Frame: At day 6
|
Complete response (CR) is defined as no episodes of vomiting and no use of rescue antiemetic medications.
Patient reported diaries will be used to measure this outcome.
|
At day 6
|
Rate of no nausea in the acute time period (0 - 24 hours post-chemotherapy)
Time Frame: At day 2
|
Patients will record daily levels of nausea after chemotherapy using a Likert scale ranging from 0-10 (0 indicating no nausea; 10 indicating maximum level of nausea).
|
At day 2
|
Rate of no nausea in the delayed time period (24 - 120 hours post-chemotherapy)
Time Frame: At day 6
|
Patients will record daily levels of nausea using a Likert scale ranging from 0-10 (0 indicating no nausea; 10 indicating maximum level of nausea).
|
At day 6
|
Rate of no nausea in the overall time period (0 - 120 hours post-chemotherapy)
Time Frame: At day 6
|
Patients will record daily levels of nausea using a Likert scale ranging from 0-10 (0 indicating no nausea; 10 indicating maximum level of nausea).
|
At day 6
|
Mean somnolence score
Time Frame: At day 6
|
Patients will record daily levels of undesired sedation using a Likert scale ranging from 0 to 10 (0 indicating no undesired sedation; 10 indicating maximum level of undesired sedation).
|
At day 6
|
Mean increased-appetite score
Time Frame: At day 6
|
Patients will record daily levels of undesired increase in appetite using a Likert scale ranging from 0 to 10 (0 indicating no undesired increase in appetite; 10 indicating maximum level of undesired increase in appetite).
|
At day 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Aimee Rolston, University of Michigan Rogel Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 28, 2020
Primary Completion (Actual)
January 3, 2024
Study Completion (Estimated)
March 1, 2024
Study Registration Dates
First Submitted
August 3, 2020
First Submitted That Met QC Criteria
August 3, 2020
First Posted (Actual)
August 7, 2020
Study Record Updates
Last Update Posted (Estimated)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 26, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dermatologic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Serotonin 5-HT3 Receptor Antagonists
- Antipruritics
- Selective Serotonin Reuptake Inhibitors
- Dexamethasone
- Olanzapine
- Ondansetron
- Fosaprepitant
- Prochlorperazine
- Neurokinin-1 Receptor Antagonists
Other Study ID Numbers
- UMCC 2019.173
- HUM00175458 (Other Identifier: University of Michigan)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecologic Cancer
-
University of LouisvilleJames Graham Brown Cancer CenterCompleted
-
Shandong UniversityCompletedGynecologic Cancer | Gynecologic DiseaseChina
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedGynecologic Cancer | Surgery | Anesthesia | Hysterectomy | Gynecologic DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingGynecologic Cancer
-
IRCCS Policlinico S. MatteoNot yet recruiting
-
Fudan UniversityGuangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Fox Chase Cancer CenterCompleted
-
University Hospital, GenevaCompletedGynecologic CancerSwitzerland
-
Fudan UniversityGuangzhou Burning Rock Bioengineering Ltd.Active, not recruiting
Clinical Trials on Ondansetron
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting
-
Seoul National University Bundang HospitalRecruiting
-
Tanta UniversityRecruitingCaesarean Section | Postoperative Nausea and Vomiting | Ondansetron LozengeEgypt
-
Halozyme TherapeuticsCompleted
-
Aquestive TherapeuticsCompleted
-
Washington University School of MedicineCompleted
-
General Hospital of Ningxia Medical UniversityCompleted
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting